Walter Stüdeli has informed the Board of the Swiss Association for Complementary Medicine Remedies SVKH that he will be stepping down as Managing Director at the 2020 General Assembly after 16 years.
The Board would like to thank him for his many years of service, which were associated with many successes.
Walter Stüdeli was campaign manager for the constitutional referendum “Future with complementary medicine” in 2009 and was responsible for implementing the key demands in the Federal Parliament.
The SVKH has him to thank for the simplified authorization of complementary and herbal medicines under the revised TPA provisions.
We have succeeded in reconciling the heterogeneous concerns of the various therapeutic directions and presenting a united front to the outside world.
Stüdeli’s broad network was of great value for many issues in the Federal Parliament.
The Board of Directors deeply regrets his resignation, but accepts the decision to hand over the administrative leadership of the association.
In future, Walter Stüdeli intends to focus more on his core competence, political lobbying.
The SVKH Board and Walter Stüdeli have indicated that they can imagine continuing to work together in the area of lobbying.
Stüdeli will continue to look after the political and media dossiers at Dakomed, and the SVKH is a member of Dakomed.
Furthermore, on Stüdeli’s initiative, the ASSGP, the SDV, pharmaSuisse and the SVKH recently decided to better coordinate political dossiers in future and to write joint submissions.
The united approach of the stakeholders is a key success factor for increasing the impact on the federal parliament, the government and the authorities.
The SVKH Board has opted for a two-stage approach for the succession plan.
In the first phase, it has drawn up a list of potential successors whom it will contact personally.
If no suitable person can be found in this way, the position will be advertised publicly.
The aim of the Board of Directors is to find a seamless successor so that the handover can take place in an orderly manner.
We are looking for a successor with specialist expertise in KPA medicinal products and political lobbying.
Training as a pharmacist or druggist would be an advantage.
It is conceivable for the Board that the task of management could be divided between two people (1. association management with medical-pharmaceutical KPA knowledge, 2. monitoring and lobbying federal parliament, support for consultation submissions, contacts with friendly associations).
The Board invites members to report potential candidates to the President, Dr. Herbert Schwabl.
Members and third parties also have the opportunity to submit their own candidacy (h.schwabl@padma.ch).
The Board of Directors decides together which persons will be invited to an interview.
All proposals and candidacies will be examined and treated confidentially.
